IP Library › Granted Patent US 9,598,683
Granted Patent B2
US 9,598,683 · App. 13/700,867 · Granted Mar 21, 2017

Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof

Inventors: Yong Hoon Chung (Seoul, KR); Hyun Sub Lee (Seoul, KR)
Assignee: MEDEXGEN INCORPORATED
C12N9/52A61K38/4893A61K49/00G01N30/96
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,598,683
App. No.
13/700,867
Granted
Mar 21, 2017
Kind
B2
Abstract

A method for purifying a non-spreading botulinum toxin that causes local muscle paralysis and a non-spreading botulinum toxin obtained thereby includes the steps of: subjecting a purified botulinum toxin type A product to ion-exchange chromatography using a controlled pH of buffer, concentration of sodium chloride (NaCl), thereby separating the botulinum toxin type A product into subfractions; and collecting a subfraction having an A260/A280 value in a specific range from the separated subfractions.

Claims (5)

1. A method for purifying a non-spreading botulinum toxin, comprising the steps of:

purifying a botulinum toxin type A by an acid precipitation;

separating subfractions from said purified botulinum toxin type A by conducting an anion-exchange chromatography having 1 ml column volume, wherein the anion-exchange chromatograph is conducted with a condition of pH 4.5-5.5 of sodium acetate as buffer and 0-1 M of sodium chloride (NaCl), wherein a loading volume of said purified botulinum toxin type A conducted by the anion-exchange chromatography ranges 0.25-2 ml, wherein the subfractions are a peak I, a peak II, and a peak III,

wherein the peak I, II, and III are obtained with 0 M, 0.02-0.2 M, and 1 M of the sodium chloride (NaCl), respectively; and

selecting a non-spreading botulinum toxin having an A260/A280 value of 0.45-0.59 from the peak I, peak II, and peak III.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2012
From: CHUNG, YONG HOON; LEE, HYUN SUB
To: MEDEXGEN INCORPORATED
Reel/Frame 029374/0664 →
Priority Claims (1)
KR 10-2010-0051076 · May 31, 2010 · national
Continuity (1)
Related Publication 20130071331A1 · Mar 21, 2013